CA-AERA-TECHNOLOGY
24.9.2020 14:02:16 CEST | Business Wire | Press release
Aera Technology today announced the general availability of the Aera Cognitive Operating System™, the world's first cloud platform for Cognitive Automation . In extending availability beyond current customers and partners, including Merck, RB, and Unilever, Aera meets the growing need of companies whose operations have been impacted by changing or uncertain market conditions.
“We’ve worked with the world's largest organizations and complex supply chains to demonstrate the value of Cognitive Automation at scale. This tight collaboration has enabled us to build the Aera Cognitive Operating System™, which is now easy to implement and scale, and therefore available to an even wider range of companies,” said Frederic Laluyaux, CEO of Aera Technology.
Alessandro de Luca, CIO of Healthcare, Merck Group, noted, “We are all running on much shorter cycles in this dynamic world, and it is impossible to process everything manually or on legacy systems. Aera's Cognitive Operating System™ has made a real difference in our ability to implement and operate a best-in-Class IBP process. This, combined with the fact that we could rely on a single, intelligent source of truth, gave us a springboard to agility.”
“Cognitive Automation plays a large role in the 4th industrial revolution,” said Nokuthula Lukhele, Project Lead, Data, and Digital Transformation, World Economic Forum. “The future of agility needs to be at the edge of decision making, and these technologies enable that,” she added.
The Aera Cognitive Operating System™ augments and enhances human decisions, providing a centralized corporate brain - adding agility to enterprise systems. By applying data crawling, machine learning, and industry models, Aera’s system makes real-time recommendations, predicts outcomes, and acts autonomously to aid complex decisions - from inventory optimization and touchless planning to order management and trade promotions.
“There is a limit of what the human mind can do with the volume of data and analytics needed to optimize a supply chain,” said Bish Sen, Head of Supply Chain Beauty & Personal Care, Transformation, Planning & Engineering at Unilever. “This is where agility is more important than accuracy, and Cognitive Automation can help unlock those levels of agility.”
“Designing and managing a supply chain that balances customer service, cost, and resiliency requires a model that constantly measures and reacts to value at risk. Kearney’s Sense & Pivot approach, combined with Aera’s Cognitive Operating System™, provides a proven solution agile enough to respond to this challenge by delivering real-time Cognitive Automation at scale for corporate boards and supply chain leaders.” - Suketu Gandhi, Partner, Global Leader - Digital Supply Chain, Kearney.
Aera Technology is hosting the Cognitive Automation Summit on September 24, 2020. This first summit dedicated to Cognitive Automation offers a unique opportunity to understand how the tectonic shift in cloud-scale and in artificial intelligence, along with radical market volatility are forcing enterprises to redefine agility. Thought leaders and pioneers from world-leading organizations will share how they leverage Aera’s Cognitive Operating System™ to achieve previously unattainable levels of financial and operational performance - without trade-offs.
For more information, visit https://cognitiveautomationsummit.com/ .
Aera also announced this week the launch of Aera Developer™, a self-service integrated development environment, which has been purpose-built for implementing Cognitive Automation at scale. It integrates each component of Data, Science, Process, and Change, so that it has all of the capabilities necessary for building Cognitive Skills, all rolled into one seamless user experience.
About Aera Technology
Aera Technology delivers the Cognitive Operating System™ that enables the Self-Driving Enterprise™. Aera understands how businesses work; makes real-time recommendations; predicts outcomes; and acts autonomously. Using proprietary data crawling, industry models, machine learning and artificial intelligence, Aera is revolutionizing how people relate to data and how organizations function. Headquartered in Mountain View, California, Aera services some of the world's largest enterprises from its global offices located in San Francisco, Bucharest, Cluj-Napoca, Paris, Munich, London, Pune, and Sydney. For more information about Aera, please visit www.aeratechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom